Cetuximab binds EGFR on target cells and its IgG1 Fc engages Fcγ receptors on NK cells/macrophages to trigger ADCC (and some CDC), resulting in lysis of EGFR-expressing cells; EGFR signaling blockade is mainly antiproliferative.